Ossiam Moderna, Inc. Transaction History

Ossiam

$5.23 Billion
Q2 2024

A detailed history of Ossiam transactions in Moderna, Inc. stock. As of the latest transaction made, Ossiam holds 19,791 shares of MRNA stock, worth $1.32 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

19,791

Previous 18,802 5.26%

Holding current value

$1.32 Million

Previous $2 Million 17.32%

% of portfolio

0.04%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$101.21 - $166.61 $100,096 - $164,777	989 Added 5.26%	19,791 $2.35 Million
Q1 2024 May 13, 2024	BUY	$85.37 - $115.44 $439,228 - $593,938	5,145 Added 37.67%	18,802 $2 Million
Q4 2023 Feb 13, 2024	BUY	$69.51 - $104.43 $3,823 - $5,743	55 Added 0.4%	13,657 $1.36 Million
Q3 2023 Nov 14, 2023	BUY	$96.41 - $126.61 $771 - $1,012	8 Added 0.06%	13,602 $1.4 Million
Q2 2023 Aug 11, 2023	SELL	$118.5 - $160.53 $159,619 - $216,233	-1,347 Reduced 9.02%	13,594 $1.65 Million
Q1 2023 May 12, 2023	SELL	$135.66 - $197.02 $349,867 - $508,114	-2,579 Reduced 14.72%	14,941 $2.29 Million
Q4 2022 Feb 13, 2023	BUY	$118.38 - $210.04 $1.48 Million - $2.62 Million	12,486 Added 248.03%	17,520 $3.15 Million
Q3 2022 Nov 14, 2022	BUY	$118.07 - $194.18 $213,824 - $351,659	1,811 Added 56.19%	5,034 $595,000
Q2 2022 Aug 12, 2022	BUY	$117.13 - $176.59 $377,509 - $569,149	3,223 New	3,223 $460,000
Q1 2022 May 13, 2022	SELL	$126.46 - $235.05 $97,247 - $180,753	-769 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$225.82 - $368.51 $3.74 Million - $6.1 Million	-16,566 Reduced 95.56%	769 $195,000
Q3 2021 Nov 12, 2021	BUY	$221.9 - $484.47 $3.85 Million - $8.4 Million	17,335 New	17,335 $6.67 Million

Others Institutions Holding MRNA

# of Institutions

1,114

Shares Held

241M

Call Options Held

9.26M

Put Options Held

12.1M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $26.1B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ossiam, based on Form 13F filings with the SEC.

News

Stay updated on Ossiam with notifications on news.

Account